TD Private Client Wealth’s Adaptive Biotechnologies ADPT Stock Holding History

TD Private Client Wealth’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23	Closed	-$645	–	1268
2021 Q4	$645	Buy	+23	New	+$705	﹤0.01%	1105

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

TD Private Client Wealth's ADPT Position: Q1 2022 in Review

TD Private Client Wealth sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 23 shares — an estimated $645 sold.

TD Private Client Wealth first reported a position in ADPT in Q4 2021 and held it in 1 quarter. The position peaked at $645 in Q4 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

TD Private Client Wealth reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
TD Private Client Wealth sold 23 Adaptive Biotechnologies shares in Q1 2022, an estimated $645.
TD Private Client Wealth first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 1 quarter.
TD Private Client Wealth's Adaptive Biotechnologies position peaked at $645 in Q4 2021.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on TD Private Client Wealth's 13F filing for Q1 2022, filed 16 Aug 2024.